Prism Medico and Pharmacy Limited (BOM:512217)

Prism Medico and Pharmacy Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Apr 1, 2023	Apr 1, 2022	Apr 1, 2021
Cash & Equivalents	-	0.65	0.84	0.96	0.55	0.84
Cash & Short-Term Investments	0.65	0.65	0.84	0.96	0.55	0.84
Cash Growth	-21.77%	-21.77%	-12.64%	73.68%	-34.51%	-24.72%
Accounts Receivable	-	35.84	36.9	47.61	48.81	135.14
Other Receivables	-	29.98	29.77	-	-	-
Receivables	-	71.42	72.26	82.74	54.8	145.25
Inventory	-	67.71	67.71	67.71	67.71	48.47
Other Current Assets	-	12.9	9.09	0.01	0.34	0.34
Total Current Assets	-	152.68	149.89	151.41	123.39	194.9
Property, Plant & Equipment	-	0.29	0.34	0.39	0.45	0.55
Long-Term Investments	-	-	-	-	-	19.38
Long-Term Deferred Tax Assets	-	2.37	2.2	2.14	1.88	0.59
Other Long-Term Assets	-	0.3	0	0	-0	-
Total Assets	-	155.65	152.43	153.93	125.72	215.42
Accounts Payable	-	-	0.31	-	-	84.44
Accrued Expenses	-	0.05	0.05	-	-	-
Other Current Liabilities	-	4.67	0.66	2.32	0.17	1.72
Total Current Liabilities	-	4.72	1.02	2.32	0.17	86.16
Other Long-Term Liabilities	-	0	0	-	-	-0
Total Liabilities	-	4.72	1.02	2.32	0.17	86.16
Common Stock	-	60.63	60.63	60.63	60.63	60.63
Retained Earnings	-	90.29	90.78	90.98	64.91	68.63
Shareholders' Equity	150.93	150.93	151.42	151.62	125.55	129.26
Total Liabilities & Equity	-	155.65	152.43	153.93	125.72	215.42
Net Cash (Debt)	0.65	0.65	0.84	0.96	0.55	0.84
Net Cash Growth	-21.77%	-21.77%	-12.64%	73.68%	-34.51%	-24.72%
Net Cash Per Share	-	0.11	0.14	0.16	0.09	0.14
Filing Date Shares Outstanding	-	6.06	6.06	6.06	6.06	6.06
Total Common Shares Outstanding	-	6.06	6.06	6.06	6.06	6.06
Working Capital	-	147.97	148.88	149.09	123.22	108.74
Book Value Per Share	24.79	24.89	24.97	25.00	20.71	21.32
Tangible Book Value	150.93	150.93	151.42	151.62	125.55	129.26
Tangible Book Value Per Share	24.79	24.89	24.97	25.00	20.71	21.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.